Who is sponsoring NCT01629680?

NCT01629680 is sponsored by Medical University of Vienna.

What drugs are being tested in NCT01629680?

Interventions in NCT01629680: Moxaverine, Placebo.

What condition does NCT01629680 study?

NCT01629680 studies Effect of Orally Administrated Moxaverine on Ocular Blood Flow.

Is NCT01629680 still recruiting?

NCT01629680 is currently completed. Last updated 26 June 2012.

Last reviewed 2012-06-26 · How we verify

NCT01629680

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized, Placebo-controlled Study Investigating the Effects of Moxaverine on Ocular Blood Flow After Oral Administration in Healthy Subjects

Completed Phase 2 Last updated 26 June 2012

What this trial tests

Phase 2 trial testing Moxaverine in Effect of Orally Administrated Moxaverine on Ocular Blood Flow in 16 participants. Completed in 1 June 2011.

Timeline

1 October 2010

Primary endpoint
1 March 2011

1 June 2011

Quick facts

Lead sponsor	Medical University of Vienna
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	basic science
Enrollment	16
Start date	1 October 2010
Primary completion	1 March 2011
Estimated completion	1 June 2011
Sites	1 location across Austria

Drugs / interventions tested

Moxaverine (MOXAVERINE) — full drug profile →
Placebo

Conditions studied

Effect of Orally Administrated Moxaverine on Ocular Blood Flow — all drugs for Effect of Orally Administrated Moxaverine on Ocular Blood Flow →

Sponsor

Medical University of Vienna

Who can join

Adults 18 to 35, any sex, with Effect of Orally Administrated Moxaverine on Ocular Blood Flow. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Choroidal and optic nerve head blood flow
Time frame: 2 weeks
Change in choroidal and optic nerve head blood flow after administration of moxaverine compared to placebo (measured before administration and 6 hours after administration)

Sponsor's own description

A number of common eye diseases such as age-related macular degeneration and glaucoma are associated with ocular perfusion abnormalities. Although this is well recognized there is not much possibility to improve blood flow to the posterior pole of the eye in these diseases. For many years, moxaverine has been used in the therapy of perfusion abnormalities in the brain, the heart and the extremities. This is based on a direct vasodilatatory effect of the drug, but also on the rheological properties of red blood cells. In two recent studies the investigators have shown that intravenous moxaverine increases choroidal and retrobulbar blood flow in healthy young subjects, in elderly people with healthy eyes and in patients with eye diseases associated with hypoperfusion. The present study aims to investigate, whether ocular blood flow is also improved after oral administration of moxaverine.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Medical University of Vienna trials

Trials by the same sponsor.

NCT07473401 — Retinal Oxygen Metabolism in Children With Myopia · not yet recruiting
NCT07511400 — The Role of NaV1.8 in Human Pain Models · EARLY_PHASE1 · not yet recruiting
NCT07516990 — Intramuscular Injection of Mashed Parathyroid Tissue Into a Forearm During Thyroid Surgery to Prevent Permanent Postoper · NA · recruiting
NCT07496437 — Is Cross-linked Hyaluronic Acid a Biologic Alternative for Alveolar Ridge Preservation? · NA · not yet recruiting
NCT07290712 — Post-Intensive Care Syndrome - Multicentre Prospective Registry Database of the DACH Region · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01629680 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of Vienna
Last refreshed: 26 June 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01629680.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing